Andrea Fortuna1, Matteo Gizzi1, Luca Bello1, Ilaria Martinelli1, Cinzia Bertolin1, Elena Pegoraro1, Maurizio Corbetta2, Gianni Sorarù3. 1. Neuromuscular Center, Department of Neurosciences, University of Padova, Italy. 2. Neuromuscular Center, Department of Neurosciences, University of Padova, Italy; Department of Neurosciences, University of Padova, Italy. 3. Neuromuscular Center, Department of Neurosciences, University of Padova, Italy. Electronic address: gianni.soraru@unipd.it.
Abstract
OBJECTIVE: To test efficacy and tolerability of edaravone in patients with amyotrophic lateral sclerosis (ALS) originating from North-Eastern Italy. METHODS: We compared 3-month and 6-month changes of ALSFRS-R score, FVC value, and MRC score of 31 consecutive patients with ALS who were treated with edaravone to those of 50 historical ALS patients who were not treated with edaravone. RESULTS: No significant difference for any functional measures was found between the two groups at each time point as compared to baseline. In treated patients, we also observed creatinine values to significantly decrease at 3 and 6 months (p = 0.0078 and 0.030, respectively) and ALSAQ5 score to significantly increase (i.e. worse quality of life) at 3 and 6 months (p = 0.0005 and 0.0078, respectively). Yet, we observed an overall safety of the medication over the 6-month period of observation. CONCLUSIONS: Our retrospective study suggests no benefit of edaravone on ALS in populations of Caucasian ancestry.
OBJECTIVE: To test efficacy and tolerability of edaravone in patients with amyotrophic lateral sclerosis (ALS) originating from North-Eastern Italy. METHODS: We compared 3-month and 6-month changes of ALSFRS-R score, FVC value, and MRC score of 31 consecutive patients with ALS who were treated with edaravone to those of 50 historical ALSpatients who were not treated with edaravone. RESULTS: No significant difference for any functional measures was found between the two groups at each time point as compared to baseline. In treated patients, we also observed creatinine values to significantly decrease at 3 and 6 months (p = 0.0078 and 0.030, respectively) and ALSAQ5 score to significantly increase (i.e. worse quality of life) at 3 and 6 months (p = 0.0005 and 0.0078, respectively). Yet, we observed an overall safety of the medication over the 6-month period of observation. CONCLUSIONS: Our retrospective study suggests no benefit of edaravone on ALS in populations of Caucasian ancestry.
Authors: Simon Witzel; André Maier; Robert Steinbach; Julian Grosskreutz; Jan C Koch; Anastasia Sarikidi; Susanne Petri; René Günther; Joachim Wolf; Andreas Hermann; Johannes Prudlo; Isabell Cordts; Paul Lingor; Wolfgang N Löscher; Zacharias Kohl; Tim Hagenacker; Christian Ruckes; Birgit Koch; Susanne Spittel; Kornelia Günther; Sebastian Michels; Johannes Dorst; Thomas Meyer; Albert C Ludolph Journal: JAMA Neurol Date: 2022-02-01 Impact factor: 18.302
Authors: Michelle Vu; Kathryn Tortorice; Jennifer Zacher; Diane Dong; Kwan Hur; Rongping Zhang; Chester B Good; Peter A Glassman; Francesca E Cunningham Journal: JAMA Netw Open Date: 2020-10-01